⬅ # 729 Stefan von Holtzbrinck|# 731 Zhu Yan ➡

# 730 Jerzy Starak 

$4.38B

Real Time Net Worth
as of 7/2/2024
-$79 (-0.00%)

# 730 Jerzy Starak 

$4.38B

Real Time Net Worth
as of 7/2/2024
-$79 (-0.00%)
OccupationChair, Polpharma
Source of WealthPharmaceuticals
Age76
ResidenceKonstancin, Poland
Marital StatusMarried
Children3
Age-Adjusted Net Worth$1.48B
Jerzy Starak
Jerzy Starak
Poland
Net worth: $4.38B

Self-Made Score 

Wealth History

Hover or tap to reveal net worth by year
Loading Chart

Biography

Overview

Jerzy Starak chairs the supervisory board of Polpharma, a leading pharmaceutical company in Poland, specializing in cardiology, neurology, and gastroenterology medications.
Starak began his entrepreneurial journey in the 1970s with Comindex, a chemical company, and later diversified his investments.
He holds stakes in ZT Kruszwica, a publicly traded agribusiness, and Herbapol, a herbal product producer.
Starak's wealth and influence stem from his successful ventures in the pharmaceutical and FMCG industries, making him one of the wealthiest individuals in Poland.

Early Life and Education

Jerzy Starak was born on December 12, 1947, in Cieszyn, Poland.
He graduated from the Warsaw University of Life Sciences (SGGW), where he pursued studies in agricultural economics.
During the communist era in Poland, Starak founded Comindex, which grew to become one of the largest Polish-owned enterprises.
Reports suggest that Starak was registered as a secret collaborator by the Security Service in 1980.
He gained valuable international experience working in Italy before returning to Poland to embark on his entrepreneurial endeavors.

Entrepreneurial Journey

In the 1990s, Starak introduced major FMCG companies like Nutricia and Colgate-Palmolive to the Polish market.
He also brought the Bols brand to Poland during this period.
In 2000, Starak acquired Polpharma, eventually controlling 64.5% of its shares by 2015.
He expanded his portfolio by acquiring Polfa Warszawa in 2012.
Starak has invested in Zakłady Tłuszczowe Kruszwica and Herbapol Lublin, diversifying his interests beyond pharmaceuticals.

Business Achievements and Recognition

Starak established the Starak Family Foundation in 2008, focusing on supporting talented young individuals.
He has received prestigious awards, including the Knight's Cross in 2003 and the Officer's Cross in 2012 of the Order of Polonia Restituta.

Personal Life

Jerzy Starak has been married twice. He has a son named Patryk from his first marriage.
His second wife is entrepreneur Anna Woźniak-Starak, with whom he has a daughter named Julia.
Piotr Woźniak-Starak, the stepson of Jerzy Starak, is a film producer and the husband of Agnieszka Woźniak-Starak.
He values his family life alongside his successful business endeavors.

Company Profile Polpharma

Polpharma, established in 1935, is the leading pharmaceutical company in Poland and a major player in Central and Eastern Europe.
The company operates with a strong international presence, offering modern drugs, substances, and innovative solutions worldwide.
Polpharma's product portfolio covers various therapeutic groups, supporting patients in the treatment and prevention of common diseases.
With five manufacturing plants and three research and development centers, Polpharma employs over 4,300 individuals.
The company's commitment to quality and innovation aligns with its mission to promote health and well-being globally.

How long would it take you to become as rich as Jerzy Starak?

If you started with $10,000 and invested an additional $500 each month at a 44.06% CAGR, it would take you 5 years to reach Jerzy Starak's net worth of $4.38B.

Is this realistic? It depends how closely the VIX-TA-Macro Advanced model performs to its history in the future. Since Grizzly Bulls launched on January 1, 2022, it's returned 48.24% compared to 16.19% for the S&P 500 benchmark.

Enter data in all but one field below, then calculate the missing value

Jerzy Starak is very wealthy, but what's stopping you from reaching that same level of success? As summarized in our five fundamental rules to wealth building, becoming wealthy in a modern capitalist economy is not complicated. There's actually only three variables:

  1. Your starting capital
  2. Your earnings after expenses
  3. The compound annual growth rate (CAGR) of your savings

Most people start with zero or very little, so if you weren't born into wealth, don't fret! The majority of the fortunate folks listed in our Grizzly Bulls’ Billionaires Index came from middle class or lower backgrounds. The most distinguishing characteristic of the group is their ability to consistently earn a high CAGR on their savings.

Every billionaire has a unique strategy to achieve high CAGR. For Jerzy Starak, Pharmaceuticals is the primary source. Whether you choose to invest your savings in your own businesses or the businesses of others is not as important. The salient piece of the puzzle is ensuring that your hard-earned savings are generating sufficient CAGR to reach your long term goals.

Most people simply invest their money in index funds and call it a day. There's nothing wrong with this approach, but it guarantees relative mediocrity. To achieve greatness, you need to invest your money to earn higher than average returns. In the long run, better investors will always finish ahead of better earners.

Source: Grizzly Bulls reporting

Methodology: Grizzly Bulls' Billionaires Index is a daily ranking of the world's billionaires and richest people. Grizzly Bulls strives to provide the most accurate net worth calculations available. We pull data from public equity markets, SEC filings, public real estate records, and other reputable sources.

The index is dynamic and updates daily at the close of U.S. stock market trading based on changes in the markets, economy, and updates to Grizzly Bulls' proprietary algorithm of personal wealth calculation. Stakes in public companies are tracked daily based on the relevant closing prices of the underlying securities. Additionally, stakes in private companies, cash, real estate, and other less easily valued assets are updated periodically through careful analysis of insider transactions, comparable public company sales / EBITDA multiples, etc.

Edited by: Lee Bailey